Crispr Therapeutics AG (CRSP) Peer Comparison

$56.82

$-0.16 (-0.28%)

As on 01-Sep-2026 16:21EDT

Market cap

$5,581 Mln

Revenue (TTM)

$13 Mln

P/E Ratio

--

P/B Ratio

3.3

Div. Yield

0 %

Edit

	Crispr Therapeutics AG (CRSP)	AC Immune SA - ADR	Adc Therapeutics SA (ADCT)
Market cap ($ Mln)	5,581	263	123
Revenue ($ Mln)	13	18	79
Net Profit ($ Mln)	-451.14	-43.16	-96.91
Net Margin (%)	-3,368.72	-246.49	-123.03
RoE (%)	-24.60	-107.75	--
Price to Earnings	--	--	--
Price-To-Book	3.29	6.14	3.42

Cashflow
Ratios

Cashflow ($ Mln)

	Crispr Therapeutics AG (CRSP)	AC Immune SA - ADR	Adc Therapeutics SA (ADCT)
Cash From Operating Activities	-345.01	-66.15	-141.17
Cash Flow from Investing Activities	-31.81	60.69	0.40
Cash from Financing Activities	426.03	-0.97	150.95
Net Cash Inflow / Outflow	--	--	--

Ratios

Profitability Ratios

	Crispr Therapeutics AG (CRSP)	AC Immune SA - ADR	Adc Therapeutics SA (ADCT)
ROCE (%)	-26.01	-84.28	-164.38
ROE (%)	-24.60	-107.75	73.43
ROA (%)	-18.35	-15.99	-20.90
EBIT Margin (%)	-3,529.79	-172.39	-53.31
Net Margin (%)	-3,368.72	-246.49	-123.03
Cash Profit Margin (%)	0.00	0.00	0.00

Growth Ratios

	Crispr Therapeutics AG (CRSP)	AC Immune SA - ADR	Adc Therapeutics SA (ADCT)
Revenue Growth (%)	-64.15	-39.45	1.97
EBIT Growth (%)	-1.92	40.04	64.72
Net Profit Growth (%)	3.56	14.56	42.98
EPS Growth (%)	10.70	13.75	57.71
Book Value Growth (%)	-7.92	-52.01	15.93

Valuation Ratios

	Crispr Therapeutics AG (CRSP)	AC Immune SA - ADR	Adc Therapeutics SA (ADCT)
Price / Earnings	-8.11	-4.51	-3.72
Price / Book Value	2.45	7.07	-2.86
Dividend Yield (%)	--	--	--
EV/EBITDA	-5.60	-3.40	-7.93
Market Cap ($ Cr)	--	--	--

Solvency Ratios

	Crispr Therapeutics AG (CRSP)	AC Immune SA - ADR	Adc Therapeutics SA (ADCT)
Debt to Equity	0.34	0.00	0.00
Short term debt to equity ratio	0.01	0.02	-0.03
Current Ratio	17.85	0.93	3.03
Quick Ratio	17.85	0.93	2.97
Interest Coverage	--	-200.97	-0.86

Operating Efficiency Ratios

	Crispr Therapeutics AG (CRSP)	AC Immune SA - ADR	Adc Therapeutics SA (ADCT)
Debtors to sales (%)	0.00	77.93	35.59
Asset Turnover	0.01	0.06	0.17
Receivable days	1,300.75	124.56	110.96
Inventory Days	--	--	537.14
Payable days	20.26	--	647.40
Cash Conversion Cycle	--	--	0.71

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly